RIP: a human protein involved in tumor necrosis factor signal transduction
View Patent ↗The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
1. A recombinant polynucleotide encoding a RIP-Thr 514 polypeptide, said polypeptide comprising at least 10 consecutive amino acid residues of the amino acid sequence set forth as SEQ ID NO:2, which consecutive amino acid residues comprise the amino acid residue 514 (Thr) of SEQ ID NO:2, wherein the polypeptide is immunologically distinguishable from RIP-Ser 514 .
2. An isolated or recombinant RIP-ACA 1540-1542 nucleic acid comprising at least 24 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540–1542 (ACA) of SEQ ID NO:1, wherein the nucleic acid hybridizes with RIP-ACA 1540-1542 cDNA but not with RIP-TCT 1540-1542 cDNA.
3. An isolated cell comprising a nucleic acid according to claim 1 .
4. A method of making an isolated RIP polypeptide, said method comprising steps: introducing a nucleic acid according to claim 1 into an isolated host cell or cellular extract, incubating said host cell or extract under conditions whereby said nucleic acid is expressed as a transcript and said transcript is expressed as a translation product comprising said polypeptide, and isolating said translation product.
5. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ1 (SEQ ID NO:2, residues 509–518).
6. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ2 (SEQ ID NO:2, residues 514–521).
7. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ3 (SEQ ID NO:2, residues 506–514).
8. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ4 (SEQ ID NO:2, residues 504–524).
9. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ5 (SEQ ID NO:2, residues 498–514).
10. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ6 (SEQ ID NO:2, residues 514–534).
11. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ7 (SEQ ID NO:2, residues 513–520).
12. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ8 (SEQ ID NO:2, residues 508–515).
13. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ9 (SEQ ID NO:2, residues 512–522).
14. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ10 (SEQ ID NO:2, residues 423–514).
15. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ11 (SEQ ID NO:2, residues 423–543).
16. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ12 (SEQ ID NO:2, residues 423–579).
17. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ13 (SEQ ID NO:2, residues 423–633).
18. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ14 (SEQ ID NO:2, residues 423–671).
19. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ15 (SEQ ID NO:2, residues 514–543).
20. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ16 (SEQ ID NO:2, residues 514–579).
21. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ17 (SEQ ID NO:2, residues 514–633).
22. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise αΔ18 (SEQ ID NO:2, residues 514–671).
23. A polynucleotide according to claim 1 , wherein said consecutive amino acid residues comprise SEQ ID NO:2.
24. A nucleic acid according to claim 2 comprising at least 36 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540–1542 (ACA) of SEQ ID NO:1.
25. A nucleic acid according to claim 2 comprising at least 48 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540–1542 (ACA) of SEQ ID NO:1.
26. A nucleic acid according to claim 2 comprising at least 72 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise the nucleotides 1540–1542 (ACA) of SEQ ID NO:1.
27. A nucleic acid according to claim 2 comprising at least 148 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540–1542 (ACA) of SEQ ID NO:1.
28. A nucleic acid according to claim 2 comprising at least 356 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540–1542 (ACA) of SEQ ID NO:1.
29. A nucleic acid according to claim 2 , wherein the consecutive nucleotides are selected from the group consisting of nucleotides 1540–1557, 1540–1563, 1540–1675, 1540–1699, 1525–1542, 1519–1542, 1507–1542, 1483–1542, 1537–1545, 1534–1548, 1528–1554, 1516–1566, 1504–1554 and 1492–1568 of SEQ ID NO:1.
30. A nucleic acid according to claim 2 comprising the nucleotide sequence set forth as SEQ ID NO:1.